- Home
- PBYI vs RDIB Comparison
PBYI vs RDIB Comparison
Compare PBYI & RDIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBYI
- RDIB
- Stock Information
- Founded
- PBYI 2010
- RDIB 1937
- Country
- PBYI United States
- RDIB United States
- Employees
- PBYI N/A
- RDIB N/A
- Industry
- PBYI Biotechnology: Pharmaceutical Preparations
- RDIB Movies/Entertainment
- Sector
- PBYI Health Care
- RDIB Consumer Discretionary
- Exchange
- PBYI Nasdaq
- RDIB Nasdaq
- Market Cap
- PBYI 263.4M
- RDIB 259.2M
- IPO Year
- PBYI N/A
- RDIB N/A
- Fundamental
- Price
- PBYI $4.95
- RDIB $11.26
- Analyst Decision
- PBYI Strong Buy
- RDIB
- Analyst Count
- PBYI 1
- RDIB 0
- Target Price
- PBYI $7.00
- RDIB N/A
- AVG Volume (30 Days)
- PBYI 418.9K
- RDIB 4.6K
- Earning Date
- PBYI 11-06-2025
- RDIB 11-12-2025
- Dividend Yield
- PBYI N/A
- RDIB N/A
- EPS Growth
- PBYI 434.29
- RDIB N/A
- EPS
- PBYI 0.97
- RDIB N/A
- Revenue
- PBYI $238,062,000.00
- RDIB $219,213,000.00
- Revenue This Year
- PBYI N/A
- RDIB $6.85
- Revenue Next Year
- PBYI N/A
- RDIB $10.86
- P/E Ratio
- PBYI $5.08
- RDIB N/A
- Revenue Growth
- PBYI 8.63
- RDIB 7.59
- 52 Week Low
- PBYI $2.32
- RDIB $5.78
- 52 Week High
- PBYI $6.07
- RDIB $14.95
- Technical
- Relative Strength Index (RSI)
- PBYI 45.94
- RDIB 47.42
- Support Level
- PBYI $5.14
- RDIB $11.23
- Resistance Level
- PBYI $5.52
- RDIB $12.21
- Average True Range (ATR)
- PBYI 0.25
- RDIB 0.35
- MACD
- PBYI -0.06
- RDIB 0.02
- Stochastic Oscillator
- PBYI 17.82
- RDIB 52.26
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About RDIB Reading International Inc Class B
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.